Comparison of the efficacy and safety of different immunization routes induced by human respiratory syncytial virus F protein with CpG adjuvant in mice

Hai Li(Shanghai East Hospital), Wenbo Xu(Shenyang Institute of Automation), Jinyuan Guo(National Institute for Viral Disease Control and Prevention), Hu Ren(National Institute for Viral Disease Control and Prevention), Yan Zhang(Memorial Sloan Kettering Cancer Center), Lei Cao(Anhui University of Finance and Economics), Qiongqiong Fang(Beijing Center for Disease Prevention and Control)
Biochemical and Biophysical Research Communications
June 9, 2022
10.1016/j.bbrc.2022.06.015
Cited by 4

Related Papers

A Novel Coronavirus from Patients with Pneumonia in China, 2019
|New England Journal of Medicine|2020|30.5k
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
|The Lancet|2020|12.6k
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
|Nature|2020|1.2k
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
|Cell|2020|802
An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of Hand Foot and Mouth Disease in Fuyang city of China
|Virology Journal|2010|473